[1] R. Siegel, Naishadham D.andJemal A., "Cancer statistics, 2012," CA Cancer J Clin, vol. 62, no. 1, pp. 10-29, 2012.
[2] M. L. Rossi, Rehman A. A.andGondi C. S., "Therapeutic options for the management of pancreatic cancer," World J Gastroenterol, vol. 20, no. 32, pp. 11142-11159, 2014.
[3] J. J. Kim and Tannock I. F., "Repopulation of cancer cells during therapy: an important cause of treatment failure," Nat Rev Cancer, vol. 5, no. 7, pp. 516-525, 2005.
[4] Q. Huang, Li F., Liu X., Li W., Shi W., Liu F. F., O'Sullivan B., He Z., Peng Y., Tan A. C., Zhou L., Shen J., Han G., Wang X. J., Thorburn J., Thorburn A., Jimeno A., Raben D., Bedford J. S.andLi C. Y., "Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy," Nat Med, vol. 17, no. 7, pp. 860-866, 2011.
[5] L. Wang, Dong P., Wang W., Huang M.andTian B., "Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem-like cells via induction of lncRNA HOTAIR," Exp Ther Med, vol. 14, no. 5, pp. 4773-4780, 2017.
[6] N. S. Ghiso and Lennon G. G., "lrp130 gene assigned to chromosome 2," In Vitro Cell Dev Biol Anim, vol. 30A, no. 11, pp. 744, 1994.
[7] N. Tsuchiya, Fukuda H., Sugimura T., Nagao M. and Nakagama H., "LRP130, a protein containing nine pentatricopeptide repeat motifs, interacts with a single-stranded cytosine-rich sequence of mouse hypervariable minisatellite Pc-1," Eur J Biochem, vol. 269, no. 12, pp. 2927-2933, 2002.
[8] S. Mili and Pinol-Roma S., "LRP130, a pentatricopeptide motif protein with a noncanonical RNA-binding domain, is bound in vivo to mitochondrial and nuclear RNAs," Mol Cell Biol, vol. 23, no. 14, pp. 4972-4982, 2003.
[9] V. K. Mootha, Lepage P., Miller K., Bunkenborg J., Reich M., Hjerrild M., Delmonte T., Villeneuve A., Sladek R., Xu F., Mitchell G. A., Morin C., Mann M., Hudson T. J., Robinson B., Rioux J. D.andLander E. S., "Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics," Proc Natl Acad Sci U S A, vol. 100, no. 2, pp. 605-610, 2003.
[10] M. Michaud, Barakat S., Magnard S., Rigal D.andBaggetto L. G., "Leucine-rich protein 130 contributes to apoptosis resistance of human hepatocarcinoma cells," Int J Oncol, vol. 38, no. 1, pp. 169-178, 2011.
[11] B. Ruzzenente, Metodiev M. D., Wredenberg A., Bratic A., Park C. B., Camara Y., Milenkovic D., Zickermann V., Wibom R., Hultenby K., Erdjument-Bromage H., Tempst P., Brandt U., Stewart J. B., Gustafsson C. M.andLarsson N. G., "LRPPRC is necessary for polyadenylation and coordination of translation of mitochondrial mRNAs," EMBO J, vol. 31, no. 2, pp. 443-456, 2012.
[12] J. Zou, Yue F., Jiang X., Li W., Yi J.andLiu L., "Mitochondrion-associated protein LRPPRC suppresses the initiation of basal levels of autophagy via enhancing Bcl-2 stability," Biochem J, vol. 454, no. 3, pp. 447-457, 2013.
[13] J. Zou, Yue F., Li W., Song K., Jiang X., Yi J.andLiu L., "Autophagy inhibitor LRPPRC suppresses mitophagy through interaction with mitophagy initiator Parkin," PLoS One, vol. 9, no. 4, pp. e94903, 2014.
[14] N. W. Blackstone, "The impact of mitochondrial endosymbiosis on the evolution of calcium signaling," Cell Calcium, vol. 57, no. 3, pp. 133-139, 2015.
[15] C. Wang and Youle R. J., "The role of mitochondria in apoptosis*," Annu Rev Genet, vol. 43, pp. 95-118, 2009.
[16] N. G. Larsson, "Somatic mitochondrial DNA mutations in mammalian aging," Annu Rev Biochem, vol. 79, pp. 683-706, 2010.
[17] K. Niforou, Cheimonidou C.andTrougakos I. P., "Molecular chaperones and proteostasis regulation during redox imbalance," Redox Biol, vol. 2, pp. 323-332, 2014.
[18] D. B. Zorov, Juhaszova M.andSollott S. J., "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," Physiol Rev, vol. 94, no. 3, pp. 909-950, 2014.
[19] T. Tian, Ikeda J., Wang Y., Mamat S., Luo W., Aozasa K.andMorii E., "Role of leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC) for anti-apoptosis and tumourigenesis in cancers," Eur J Cancer, vol. 48, no. 15, pp. 2462-2473, 2012.
[20] H. Y. Zhang, Ma Y. D., Zhang Y., Cui J.andWang Z. M., "Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer," J Clin Pathol, vol. 70, no. 5, pp. 383-389, 2017.
[21] L. E. Drake, Springer M. Z., Poole L. P., Kim C. J.andMacleod K. F., "Expanding perspectives on the significance of mitophagy in cancer," Semin Cancer Biol, vol. 47, pp. 110-124, 2017.
[22] E. G. Chiorean, Von Hoff D., Wan Y., Margunato-Debay S., Botteman M.andGoldstein D., "Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer," Cancer Manag Res, vol. 10, pp. 1389-1396, 2018.
[23] D. D. Von Hoff, Ervin T., Arena F. P., Chiorean E. G., Infante J., Moore M., Seay T., Tjulandin S. A., Ma W. W., Saleh M. N., Harris M., Reni M., Dowden S., Laheru D., Bahary N., Ramanathan R. K., Tabernero J., Hidalgo M., Goldstein D., Van Cutsem E., Wei X., Iglesias J.andRenschler M. F., "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine," N Engl J Med, vol. 369, no. 18, pp. 1691-1703, 2013.
[24] G. K. Patel, Khan M. A., Bhardwaj A., Srivastava S. K., Zubair H., Patton M. C., Singh S., Khushman M.andSingh A. P., "Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK," Br J Cancer, vol. 116, no. 5, pp. 609-619, 2017.
[25] J. Zou, Li W., Misra A., Yue F., Song K., Chen Q., Guo G., Yi J., Kimata J. T.andLiu L., "Correction: The viral restriction factor Tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with Beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy," J Biol Chem, vol. 294, no. 13, pp. 5211, 2019.
[26] J. Zou, Li W., Misra A., Yue F., Song K., Chen Q., Guo G., Yi J., Kimata J. T.andLiu L., "The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy," J Biol Chem, vol. 290, no. 11, pp. 7269-7279, 2015.
[27] R. L. Siegel, Miller K. D.andJemal A., "Cancer Statistics, 2017," CA Cancer J Clin, vol. 67, no. 1, pp. 7-30, 2017.
[28] A. M. Storniolo, Enas N. H., Brown C. A., Voi M., Rothenberg M. L.andSchilsky R., "An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma," Cancer, vol. 85, no. 6, pp. 1261-1268, 1999.
[29] J. H. Lu, Shi Z. F. and Xu H., "The mitochondrial cyclophilin D/p53 complexation mediates doxorubicin-induced non-apoptotic death of A549 lung cancer cells," Mol Cell Biochem, vol. 389, no. 1-2, pp. 17-24, 2014.
[30] X. Li, Lv L., Zheng J., Zhou J., Liu B., Chen H., Liang C., Wang R., Su L., Li X.andFan D., "The significance of LRPPRC overexpression in gastric cancer," Med Oncol, vol. 31, no. 2, pp. 818, 2014.
[31] S. Bhattacharya, Pal K., Sharma A. K., Dutta S. K., Lau J. S., Yan I. K., Wang E., Elkhanany A., Alkharfy K. M., Sanyal A., Patel T. C., Chari S. T., Spaller M. R.andMukhopadhyay D., "GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways," PLoS One, vol. 9, no. 12, pp. e114409, 2014.
[32] F. Vandin, Clay P., Upfal E.andRaphael B. J., "Discovery of mutated subnetworks associated with clinical data in cancer," Pac Symp Biocomput, pp. 55-66, 2012.